Oligonucleotide (siRNA) · Gene silencing: protein kinase N3 (PKN3) mRNA (PKN3) · developed by Silence Therapeutics GmbH
Atu027 is a lipoplexed formulation of short-interfering RNAs directed against PKN3, encapsulated in cationic and fusogenic lipids that promote uptake by tumor cells. The siRNAs bind PKN3 mRNA to inhibit its translation. It is studied in advanced solid tumors and pancreatic ductal carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01808638 | Phase 1/2 | Carcinoma, Pancreatic Ductal | Completed | SLN |
| NCT00938574 | Phase 1 | Advanced Solid Tumors | Completed | SLN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsCarcinoma, Pancreatic Ductal
Updated Nov 1, 2026. Something wrong or missing? Report it on the SLN page.
See SLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLN catalysts and pipeline →